Refine by
748 results found
-
Regulatory Comment on Medicaid
Regulatory comment opposing the Arizona Medicaid Waiver Amendment Request, as the proposed rule would create unnecessary barriers to enrollment and access to care. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter to Congressional leaders, urging greater transparency and oversight regarding potential federal agency Reduction-in-Force and reorganization plans that would impact our nation’s scientific enterprise and public health infrastructure. -
Letter to Congressional Leadership on Medicaid and Mental Health Funding
Letter with the Partnership to Protect Coverage expressing deep alarm and strong opposition to the devastating Medicaid cuts being considered for inclusion in the FY25 budget reconciliation package. -
Insurance Status and Mental Health Care during the COVID-19 Pandemic
According to new research analyzing data from the Mental and Substance Use Disorder Prevalence Study, which took place during the first two years of the COVID-19 pandemic, adults with a mental health diagnosis and no insurance were less likely to have received outpatient mental health treatment in the past year compared to privately insured adults – just 31% versus 62%.
-
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter calling on House and Senate appropriators to reject the proposed cuts to the Department of Health and Human Services (HHS), including the National Institutes of Health, that were included in the leaked copy of the HHS FY 2026 budget “Passback” document. -
Letter to Congressional Committee Leadership on Medicaid and Mental Health Funding
Letter to Congressional Leaders with Primary Care Collaborative urging rejections of proposals to cut Medicaid. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter urging Congress to robustly fund NIH at least $51.303 billion for FY 26. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter urging Congress to fund the FDA’s Neurology Drug Program at $5 million in FY 26. -
Letter to Congressional Committee Leadership on Research and Treatment Innovation and Mental Health Funding
Letter encouraging Congress to restore funding to $680 million for the BRAIN Initiative for Fiscal Year (FY) 2026. -
Statement on Mental Health Funding
Statement opposing the recent program funding rescissions and staffing cuts at SAMHSA and restructuring of HHS that could lead to additional weakening of critical substance use and mental health services.